Rocket Pharmaceuticals reduces ATM offering capacity to $180M, suspends sales

ROCKET PHARMACEUTICALS, INC.

Original $200M ATM capacity reduced to $180M via amendment to Sales Agreement with Cowen.
Company sold $65.9M of shares to date; remaining availability is ~$114.1M.
ATM prospectus suspended; no further sales until new prospectus or registration statement filed.
Amendment effective September 12, 2023; Amended Sales Agreement remains in full force.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ROCKET PHARMACEUTICALS, INC. amended Sales Agreement with Cowen and Company, LLC valued at $180,000,000 (effective 2023-09-12).

Action: amendment
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: $180,000,000
Effective: 2023-09-12

Exact text from the filing

(the “ Company ”) entered into a sales agreement (the “ Sales Agreement ”) with Cowen and Company, LLC (“ Cowen ”) pursuant to which the Company may, from time to time, sell shares of its common stock, par value $0.01 per

View on SEC.gov

Browse all material agreements →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-043736

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.